Portal de Periódicos da CAPES

SARS-CoV-2 seroprevalence and neutralizing activity in donor and patient blood

2020; Nature Portfolio; Volume: 11; Issue: 1 Linguagem: Inglês

10.1038/s41467-020-18468-8

2041-1723

Dianna L. Ng, Gregory M. Goldgof, Brian R. Shy, Andrew G. Levine, Joanna Balcerek, Sagar P. Bapat, John Prostko, Mary A. Rodgers, Kelly E. Coller, Sandra Pearce, Sergej Franz, Li Du, Mars Stone, Satish K. Pillai, Alicia Sotomayor-González, Venice Servellita, Claudia Sanchez San Martin, Andrea Granados, Dustin R. Glasner, Lucy M. Han, Kent Truong, Naomi Akagi, David N. Nguyen, Neil M. Neumann, Daniel Qazi, Elaine Hsu, Wei Gu, Yale A. Santos, Brian Custer, Valerie Green, Phillip Williamson, Nancy K. Hills, Chuanyi M. Lu, Jeffrey D. Whitman, Susan L. Stramer, Candace Wang, Kevin Reyes, Jill Hakim, Kirk Sujishi, Fariba Alazzeh, Lori Pham, Edward C. Thornborrow, Ching-Ying Oon, Steve Miller, Theodore W. Kurtz, Graham Simmons, John Hackett, Michael P. Busch, Charles Y. Chiu,

SARS-CoV-2 detection and testing

Abstract Given the limited availability of serological testing to date, the seroprevalence of SARS-CoV-2-specific antibodies in different populations has remained unclear. Here, we report very low SARS-CoV-2 seroprevalence in two San Francisco Bay Area populations. Seroreactivity was 0.26% in 387 hospitalized patients admitted for non-respiratory indications and 0.1% in 1,000 blood donors in early April 2020. We additionally describe the longitudinal dynamics of immunoglobulin-G (IgG), immunoglobulin-M (IgM), and in vitro neutralizing antibody titers in COVID-19 patients. The median time to seroconversion ranged from 10.3–11.0 days for these 3 assays. Neutralizing antibodies rose in tandem with immunoglobulin titers following symptom onset, and positive percent agreement between detection of IgG and neutralizing titers was >93%. These findings emphasize the importance of using highly accurate tests for surveillance studies in low-prevalence populations, and provide evidence that seroreactivity using SARS-CoV-2 anti-nucleocapsid protein IgG and anti-spike IgM assays are generally predictive of in vitro neutralizing capacity.